Morgan Stanley reaffirmed their hold rating on shares of Horizon Pharma Inc. (NASDAQ:HZNP) in a research report sent to investors on Wednesday morning. Morgan Stanley currently has a $24.00 target price on the biopharmaceutical company’s stock.
Other analysts also recently issued reports about the company. Mizuho reiterated a buy rating and set a $30.00 target price (up from $24.00) on shares of Horizon Pharma in a research report on Wednesday, August 10th. Brean Capital reissued a buy rating and set a $30.00 price target on shares of Horizon Pharma in a report on Thursday, July 14th. Zacks Investment Research cut Horizon Pharma from a buy rating to a hold rating in a report on Tuesday, July 12th. BMO Capital Markets reissued an outperform rating and set a $30.00 price target on shares of Horizon Pharma in a report on Tuesday, September 13th. Finally, Vetr raised Horizon Pharma from a hold rating to a buy rating and set a $19.82 price target for the company in a report on Tuesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Horizon Pharma has an average rating of Buy and a consensus target price of $30.00.
Horizon Pharma (NASDAQ:HZNP) opened at 18.77 on Wednesday. The company’s market cap is $3.02 billion. The firm’s 50-day moving average price is $19.59 and its 200-day moving average price is $17.72. Horizon Pharma has a one year low of $12.86 and a one year high of $23.70.
Horizon Pharma (NASDAQ:HZNP) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.12. The firm earned $257.40 million during the quarter, compared to the consensus estimate of $235.43 million. Horizon Pharma had a positive return on equity of 23.46% and a negative net margin of 0.34%. The company’s revenue was up 48.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.39 EPS. On average, equities research analysts forecast that Horizon Pharma will post $2.15 earnings per share for the current fiscal year.
In other Horizon Pharma news, EVP Jeffrey W. Sherman sold 2,900 shares of the company’s stock in a transaction dated Tuesday, August 2nd. The stock was sold at an average price of $20.00, for a total value of $58,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 2.10% of the stock is owned by company insiders.
Several large investors have recently made changes to their positions in HZNP. Canada Pension Plan Investment Board acquired a new stake in shares of Horizon Pharma during the first quarter valued at approximately $114,000. Societe Generale acquired a new stake in shares of Horizon Pharma during the second quarter valued at approximately $117,000. SG Americas Securities LLC acquired a new stake in shares of Horizon Pharma during the second quarter valued at approximately $117,000. Exane Derivatives acquired a new stake in shares of Horizon Pharma during the first quarter valued at approximately $166,000. Finally, Nuveen Asset Management LLC acquired a new stake in shares of Horizon Pharma during the second quarter valued at approximately $176,000. Institutional investors own 85.25% of the company’s stock.
Horizon Pharma Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Receive News & Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.